series-b
Stage
3
Investors
About
AAVantgarde develops next-generation gene therapies targeting inherited retinal disorders such as Stargardt disease and Usher 1B syndrome by delivering large genes to address the root cause of these conditions.
Explore AAVantgarde's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.